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Objectives: To assess antibiotic susceptibility of community-acquired respiratory tract isolates from Ivory Coast,
Kenya, Democratic Republic of Congo (DRC) and Senegal in 2011–14.
Methods: Bacterial isolates were collected and MICs determined using Etestw for all antibiotics except erythro-
mycin, for which testing was by disc diffusion. Susceptibility was assessed using CLSI, EUCAST and pharmacoki-
netic/pharmacodynamic (PK/PD) breakpoints. For macrolide interpretation, CLSI breakpoints were adjusted for
incubation in CO2.
Results: Susceptibility to penicillin (using CLSI oral or EUCAST breakpoints) was low among isolates
of Streptococcus pneumoniae from the DRC and Kenya (17.4% and 19%, respectively) but higher among isolates
from the Ivory Coast (70%) and Senegal (85.7%). Penicillin susceptibility using CLSI iv breakpoints was higher
in all countries, but still only 69.6% in the DRC. Macrolide susceptibility (based on CLSI erythromycin disc
diffusion breakpoints) was also low in Kenya (65%) but 87%–100% elsewhere. Haemophilus influenzae were
only collected in the DRC and Senegal, with b-lactamase prevalence of 39% and 4%, respectively. Furthermore,
b-lactamase-negative ampicillin-resistant (BLNAR) isolates were found in DRC (four isolates, 17%), but only two
isolates were found in Senegal (by EUCAST definition). Amoxicillin/clavulanic acid in vitro susceptibility was 73.9%
in the DRC and 100% in Senegal based on CLSI breakpoints, but this reduced to 65.2% in the DRC when BLNAR
rates were considered. Clarithromycin susceptibility was .95% in both countries.
Conclusions: There was considerable variability in antibiotic susceptibility among the African countries participat-
ing in the surveillance programme. Thus, continued surveillance is necessary to track future changes in antibiotic
resistance. Use of EUCAST versus CLSI breakpoints showed profound differences for cefaclor and ofloxacin against
S. pneumoniae, with EUCAST showing lower susceptibility.
Introduction
In Africa, acute respiratory infections are the cause of death in
16% of children under 5 years old.1 Despite this significant health
problem, few studies report updates on antimicrobial susceptibil-
ity of respiratory pathogens in this continent and the studies to
date are often from large-scale global surveillance programmes
that present combined data for the entire continent rather than
individual countries.2,3 Local antimicrobial surveillance data in
individual African countries are very limited,4 with most of the
data coming from South Africa.5 However, recent reviews of stud-
ies of antimicrobial susceptibility in Africa have shown that
resistance patterns vary within Africa5,6 and results from one
country should not be assumed to apply to another. This makes
surveillance at the country and local level very valuable for guiding
empirical therapy, especially in sub-Saharan Africa, where health-
care providers and patients must often rely on affordable first-line
antibiotics that may have lost their clinical effectiveness.2
Knowledge of resistance patterns is especially important for
community-acquired pneumonia (CAP), since it is usually treated
empirically without identification of the causative agent or its
antibiogram.
The Survey of Antibiotic Resistance (SOAR) is an ongoing
surveillance study of key respiratory pathogens. SOAR has
# The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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been monitoring antimicrobial resistance in Africa, the Middle
East, Latin America, Asia-Pacific and the Commonwealth
of Independent States countries since 2002. For this report,
recent SOAR data from hospitals in the Democratic Republic of
Congo, Ivory Coast, Kenya and the Republic of Senegal were ana-
lysed to provide a picture of the current state of antimicrobial
susceptibility.
Materials and methods
Collaborating centres
Isolates were collected from five sites in four countries: CUK/RDC,
Democratic Republic of Congo; Institut Pasteur de Coˆte d’Ivoire, Ivory
Coast; Universite´ Cheikh Anta Diop, Senegal; Kenyatta National Hospital,
Kenya and Aga Khan University Hospital, Kenya.
Clinical isolates (from outpatients who attended the
university/national hospitals)
During 2011–14, a total of 277 clinical respiratory isolates, comprising
231 isolates of Streptococcus pneumoniae (23 from the Democratic
Republic of Congo, 110 from the Ivory Coast, 84 from Kenya and 14
from Senegal) and 46 isolates of Haemophilus influenzae were analysed
(23 from the Democratic Republic of Congo and 23 from Senegal).
Paediatric patients (≤12 years old) accounted for 93 (33.6%) isolates,
adult patients (13 – 64 years old) accounted for 170 (61.4%) isolates
and the elderly (≥65 years) accounted for 14 (5.1%) isolates. Isolates ori-
ginated from a variety of infection sources, including blood, tracheal
aspirate, bronchoalveolar lavage, middle ear effusion, pleural aspirate
and sputum. Organisms were identified using conventional methods
(optochin susceptibility/bile solubility for S. pneumoniae and X and V
factor requirement for H. influenzae). Duplicate isolates from the same
patient were excluded from analysis.
Susceptibility testing
MICs were determined in selected local laboratories using the gradient
strip Etestw susceptibility method according to the manufacturer’s instruc-
tions (bioMe´rieux, Marcy l’E´toile, France). b-Lactamase production was
determined by a chromogenic cephalosporin (nitrocefin) disc method.
Disc diffusion susceptibility testing was carried out according to CLSI
methodology.7 Study drugs for S. pneumoniae evaluated by Etestw varied
by country and included penicillin, amoxicillin, amoxicillin/clavulanic acid,
azithromycin, cefaclor, ceftriaxone, cefuroxime, chloramphenicol, clarithro-
mycin, clindamycin, erythromycin (only in Kenya by Etestw), levofloxacin,
moxifloxacin, ofloxacin, tetracycline and trimethoprim/sulfamethoxazole.
Study drugs for H. influenzae evaluated by Etestw included amoxicillin/
clavulanic acid, ampicillin, azithromycin, cefaclor, cefixime, cefuroxime,
ciprofloxacin, clarithromycin, levofloxacin, ofloxacin and trimethoprim/
sulfamethoxazole. Erythromycin was also evaluated by disc diffusion.
Susceptibility to the study drugs was calculated based on CLSI break-
points,8 except for macrolides and clindamycin, where Etestw breakpoints
for incubation in CO2 were used. In addition, susceptibility based on the
EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints
was analysed where applicable to assess whether adoption of these break-
points would affect rates of susceptibility.9,10 EUCAST and PK/PD break-
points were not evaluated for macrolides (except erythromycin for
EUCAST) or clindamycin because, unlike CLSI, these are not adjusted for
incubation in CO2 by bioMe´rieux. Breakpoints are shown in Table 1.
Quality control and data analysis
Quality control strains Staphylococcus aureus ATCC 29213, S. pneumoniae
ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766,
Escherichia coli ATCC 25922 and E. coli ATCC 32518 were included on
each day of testing. Results of susceptibility testing were accepted if the
results of the control strains were within published limits. Differences in
susceptibility between age groups and countries were assessed for statis-
tical significance with Fisher’s exact test using XLSTAT version 2011.1.05. A
P value ,0.05 was considered statistically significant.
Results
S. pneumoniae
Of the 231 S. pneumoniae isolates collected in the four African
countries, 85 were from sputum (36.8%), 62 from blood
(26.8%), 42 from ear effusion (18.2%), 25 from tracheal aspirate
or bronchoalveolar lavage (10.8%) and 17 from pleural aspirate
(7.4%). Paediatric patients (≤12 years old) contributed 82
(35.5%) isolates, adults (13–64 years old) 139 isolates (60.2%)
and the elderly (≥65 years) 10 isolates (4.3%).
Summary MIC and susceptibility data for S. pneumoniae are
shown in Table 2. MIC distribution data are given in Table 3.
By CLSI penicillin iv (non-meningitis) breakpoints, .95% of
S. pneumoniae were penicillin susceptible in all countries, except
Democratic Republic of Congo (69.6%), whereas based on CLSI
penicillin oral and EUCAST breakpoints, the proportion of penicillin-
susceptible isolates was 85.7% in Senegal (albeit with small sam-
ple size of 14 isolates), 70% in Ivory Coast, 19% in Kenya and
17.4% in Democratic Republic of Congo (Table 2).
The most consistent in vitro activity in the region was shown by
levofloxacin, with .98% of pneumococcal isolates showing sus-
ceptibility by all three breakpoints in all four countries. Similarly,
100% of isolates were susceptible to amoxicillin/clavulanic acid
(and by inference of amoxicillin alone) by both CLSI and PK/PD
breakpoints in Ivory Coast and Senegal, and .95% susceptible
by these breakpoints in Kenya. Cefuroxime was very active against
isolates from the Ivory Coast and Senegal with.90% susceptibil-
ity using all three breakpoints. However, isolates from the
Democratic Republic of Congo and Kenya showed ,80% suscep-
tibility by CLSI and PK/PD breakpoints and 30.4% and 54.8%,
respectively, using the EUCAST breakpoint. Macrolides were active
against.95% of S. pneumoniae in Ivory Coast and Senegal, 87%
in Democratic Republic of Congo, but only 64.1% in Kenya, based
on erythromycin susceptibility using CLSI breakpoints. Using all
three breakpoints, trimethoprim/sulfamethoxazole activity was
low in Democratic Republic of Congo (73.9% –78.3%), Ivory
Coast (50%–54.6%) and Senegal (14.3%–21.4%), as was tetra-
cycline activity in Kenya (,50%).
Cefaclor and ofloxacin demonstrated significant variation in
percentage susceptibility when different breakpoints were
applied. Cefaclor was active against 60% of isolates from the
Ivory Coast and 78.6% from Senegal using CLSI breakpoints,
whereas the PK/PD breakpoint resulted in 17.3% and 42.9% sus-
ceptibility, respectively, and EUCAST breakpoints showed non-
susceptibility in both countries. Percentage susceptibility values
for ofloxacin using CLSI breakpoints were .85% in Democratic
Republic of Congo, Ivory Coast and Senegal, but only 43.5%,
1.8% and 0%, respectively, using EUCAST breakpoints.
Figure 1 shows the direct comparison between countries of
percentage antimicrobial susceptibility (based on CLSI break-
points) tested by at least two countries collecting a minimum of
20 isolates. Isolates recovered from patients in the Ivory Coast
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showed significantly higher susceptibility to cefuroxime and
penicillin than both Kenya and Democratic Republic of Congo.
Susceptibility to trimethoprim/sulfamethoxazole was lowest
(14.3%) in Senegal but was 50% in Ivory Coast and 73.9% in
Democratic Republic of Congo. Antimicrobial susceptibility was
generally lower in Kenya than in the two other countries, with sig-
nificantly lower susceptibility to azithromycin (65.6%) compared
with Democratic Republic of Congo and to cefuroxime and eryth-
romycin compared with Ivory Coast.
CLSI guidelines indicate that isolates susceptible to penicillin G
(MIC ≤0.06 mg/L) can be reported as susceptible to amoxicillin/
clavulanic acid, ceftriaxone, cefaclor and cefuroxime. Data from
this study (all isolates combined) confirmed this, in that all
penicillin-susceptible S. pneumoniae were also susceptible to the
b-lactam antibiotics listed above apart from 24 out of 114
penicillin-susceptible isolates (21.1%) that were non-susceptible
to cefaclor. However, the reverse was not always found. All 206
penicillin-non-susceptible isolates were amoxicillin/clavulanic
acid susceptible and all but one was ceftriaxone susceptible. For
cefuroxime, 74.2% of penicillin-non-susceptible isolates were sus-
ceptible. However, only 14.5% of penicillin-non-susceptible
S. pneumoniae were cefaclor susceptible (27.7%). A similar ‘expert
rule’ is provided by EUCAST but for penicillins only, i.e. amoxicillin/
clavulanic acid (amoxicillin). However, unlike CLSI, individual
breakpoints are not provided by EUCAST for amoxicillin/clavula-
nate to make this comparison.
Prevalence of antibiotic susceptibility among PSSP, PISP
and PRSP isolates (based on CLSI penicillin oral
breakpoints)
Combining all isolates from the four African countries, susceptibil-
ity was compared among penicillin-susceptible S. pneumoniae
(PSSP), penicillin-intermediate S. pneumoniae (PISP) and penicillin-
resistant S. pneumoniae (PRSP) isolates for those agents where
at least 20 isolates were tested in at least two penicillin suscepti-
bility subsets (Figure 2). PSSP isolates were 100% susceptible to
amoxicillin/clavulanic acid, cefuroxime and levofloxacin and
.90% were susceptible to clarithromycin, ofloxacin and erythro-
mycin. The activities of cefaclor and trimethoprim/sulfamethoxa-
zole were lower, at 72% and 51%, respectively. Among the PISP
isolates, .95% were susceptible to amoxicillin/clavulanic acid,
Table 1. MIC breakpoints (mg/L) used for S. pneumoniae and H. influenzae isolates
S. pneumoniae H. influenzae All species
CLSI EUCAST CLSI EUCAST
PK/PD
Antimicrobial S I R S I R S I R S I R (S only)
Amoxicillin ≤2 4 ≥8 NA NA NA NT NT NT NT NT NT ≤2
AMCa ≤2 4 ≥8 NA NA NA ≤4 — ≥8 ≤2 — ≥4 ≤2 (≤4)
Ampicillin NT NT NT NT NT NT ≤1 2 ≥4 ≤1 — ≥2 NA
Azithromycinb ≤4 8 ≥16 NA NA NA ≤8 — —b NA NA NA NA
Cefaclor ≤1 2 ≥4 ≤0.03 0.06–0.5 ≥1 ≤8 16 ≥32 NA NA NA ≤0.5
Cefixime NA NA NA NA NA NA ≤1 — — ≤0.12 — ≥0.25 ≤1
Ceftriaxone ≤1 2 ≥4 ≤0.5 1-2 ≥4 NT NT NT NT NT NT ≤1
Cefuroximec ≤1 2 ≥4 ≤0.25 0.5 ≥1 ≤4 8 ≥16 ≤0.12 0.25–1 ≥2 ≤1
Ciprofloxacin NT NT NT NT NT NT ≤1 — — ≤0.5 — ≥1 ≤1
Chloramphenicol ≤4 — ≥8 ≤8 — ≥16 NT NT NT NT NT NT NA
Clarithromycin ≤0.5 1 ≥2 NA NA NA ≤16 32 ≥64 NA NA NA NA
Clindamycinb ≤0.5 1 ≥2 NA NA NA NA NA NA NA NA NA NA
Erythromycinb ≤1 2 ≥4 ≤1 2 ≥4 NT NT NT NT NT NT NA
Levofloxacin ≤2 4 ≥8 ≤2 — ≥4 ≤2 — — ≤1 — ≥2 ≤2
Moxifloxacin ≤1 2 ≥4 ≤0.5 — ≥1 NT NT NT NT NT NT ≤1
Ofloxacin ≤2 4 ≥8 ≤0.12 0.25–4 ≥8 ≤2 — — ≤0.5 — ≥1 NA
Penicillin (oral) ≤0.06 0.12–1 ≥2 ≤0.06 0.12–2 ≥4 NA NA NA NA NA NA NA
Penicillin (iv)d ≤2 4 ≥8 notee NA NA NA NA NA NA NA NA NA
Tetracycline ≤1 2 ≥4 ≤1 2 ≥4 NT NT NT NT NT NT NA
SXT ≤0.5 1-2 ≥4 ≤1 2 ≥4 ≤0.5 1-2 ≥4 ≤0.5 1 ≥2 ≤0.5
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole; S, susceptible; I, intermediate; R, resistant; NA, not applicable; NT, not tested.
aTested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD breakpoint based on a high dose
(4 g of amoxicillin with 250 mg of clavulanic acid per day for adults) is shown in parentheses.
bbioMe´rieux Etestw breakpoints for incubation in CO2.
cBreakpoints used are for cefuroxime axetil.
dParenteral non-meningitis breakpoints. EUCAST do not give iv breakpoints.
eEUCAST do not give iv breakpoints but dose-specific susceptible breakpoints are noted for pneumonia: 1.2 g×4 (MIC ≤0.5 mg/L¼susceptible), 1.2 g×6
or 2.4 g×4 (MIC ≤1 mg/L¼susceptible) and 2.4 g×6 (MIC ≤2 mg/L¼susceptible).
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Table 2. MIC and susceptibility results for S. pneumoniae isolates
Country/antimicrobial n
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
50% 90% min max %S %I %R %S %S %I %R
Democratic Republic of Congo
azithromycina 23 0.5 2 0.03 16 91.3 0 8.7 NA NA NA NA
cefixime 23 0.25 2 ≤0.015 32 NA NA NA 87.0 NA NA NA
cefuroximeb 23 0.5 4 0.03 32 78.3 8.7 13.0 78.3 30.4 34.8 34.8
levofloxacin 23 0.25 1 0.004 2 100 0 0 100 100 0 0
ofloxacin 23 0.25 1 0.004 .32 95.7 0 4.4 NA 43.5 52.2 4.4
penicillin (oral) 23 0.5 8 0.06 32 17.4 47.8 34.8 NA 17.4 52.2 30.4
penicillin (iv) 23 0.5 8 0.06 32 69.6 17.4 13.0 NA 52.2–69.6 NA NA
SXT 23 0.25 .32 0.004 .32 73.9 4.4 21.7 73.9 78.3 0 21.7
erythromycinc 23 NT NT NT NT 87.0 4.3 8.7 NA 87.0 0.0 13.0
Ivory Coast
AMCd,e 110 0.03 0.12 ≤0.015 2 100 0 0 100 (100) NA NA NA
cefaclor 110 1 4 0.25 64 60.0 22.7 17.3 17.3 0 17.3 82.7
cefuroxime 110 0.06 0.25 ≤0.015 1 100 0 0 100 97.3 1.8 0.9
clarithromycina 110 0.03 0.06 ≤0.015 256 95.5 0 4.5 NA NA NA NA
levofloxacin 110 1 1 0.25 8 98.2 0.9 0.9 98.2 98.2 0 1.8
ofloxacin 110 2 4 0.015 32 86.4 9.1 4.5 NA 1.8 93.6 4.6
penicillin (oral) 110 0.03 0.5 ≤0.002 4 70.0 25.5 4.5 NA 70.0 28.2 1.8
penicillin (iv) 110 0.03 0.5 ≤0.002 4 98.2 1.8 0 NA 93.7–98.2 NA NA
SXT 110 0.5 4 0.015 32 50.0 26.4 23.6 50.0 54.6 21.8 23.6
erythromycinc 110 NT NT NT NT 96.4 1.8 1.8 NA 93.6 4.6 1.8
Kenya
amoxicillin 64 0.5 2 ≤0.015 16 92.2 1.6 6.2 92.2 NA NA NA
AMCd,e 84 0.25 2 ≤0.015 .256 95.2 1.2 3.6 95.2 (96.4) NA NA NA
azithromycin 64 2 .256 0.25 .256 65.6 6.3 28.1 NA NA NA NA
ceftriaxone 84 0.25 1 0.008 8 96.4 1.2 2.4 96.4 82.1 15.5 2.4
cefuroxime 84 0.25 4 ≤0.015 32 66.7 17.9 15.5 66.7 54.8 4.8 40.5
chloramphenicol 64 0.25 .256 0.03 .256 68.7 0.0 31.3 NA 73.4 0 26.6
erythromycina 64 0.25 .256 0.06 .256 64.1 3.1 32.8 NA 64.1 3.1 32.8
levofloxacin 20 0.5 1 0.25 1 100 0 0 100 100 0 0
moxifloxacin 84 0.12 0.25 0.03 0.5 100 0 0 100 100 0 0
penicillin (oral) 84 1 2 ≤0.015 .256 19.0 60.7 20.2 NA 19.0 69.0 4.8
penicillin (iv) 84 1 2 ≤0.015 .256 95.2 1.2 3.6 NA 46.4–95.2 NA NA
tetracycline 64 8 32 0.06 .256 46.8 1.6 51.6 NA 46.9 1.6 51.6
Senegal
AMCd,e 14 ≤0.015 0.03 ≤0.015 0.03 100 0 0 100 (100) NA NA NA
cefaclor 14 1 2 0.12 2 78.6 21.4 0 42.9 0 42.9 57.1
cefixime 14 0.5 2 0.12 2 NA NA NA 85.7 0 0 0
cefuroxime 14 0.06 0.25 ≤0.015 0.5 100 0 0 100 92.9 7.1 0
clarithromycina 14 0.06 0.12 ≤0.015 0.12 100 0 0 NA NA NA NA
clindamycin 14 0.12 0.25 0.06 0.25 100 0 0 NA NA NA NA
levofloxacin 14 0.5 1 0.5 1 100 0 0 100 100 0 0
ofloxacin 14 2 2 1 2 100 0 0 NA 0 100 0
penicillin (oral) 14 0.03 0.12 ≤0.015 0.12 85.7 14.3 0 NA 85.7 14.3 0
penicillin (iv) 14 0.03 0.12 ≤0.015 0.12 100 0 0 NA 100 NA NA
SXT 14 4 32 0.06 32 14.3 28.6 57.1 14.3 21.4 21.4 57.1
erythromycinc 14 NT NT NT NT 100 0 0 NA 100 0 0
S, susceptible; I, intermediate; R, resistant; NA, no breakpoint data available (NA for azithromycin, clarithromycin and clindamycin by PK/PD and EUCAST
and for erythromycin by EUCAST because Etestw breakpoints in CO2 not available); NT, not tested for MIC; SXT, trimethoprim/sulfamethoxazole; AMC,
amoxicillin/clavulanic acid.
abioMe´rieux Etestw breakpoints for incubation in CO2.
bBreakpoints used are for cefuroxime axetil.
cUsing S/I/R zone diameters (mm) of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).
dAmoxicillin/clavulanic acid PK/PD susceptibility at high dose shown in parentheses.
eFor S. pneumoniae susceptibility to amoxicillin alone can be inferred from amoxicillin/clavulanic acid data.
Kacou-Ndouba et al.
i24
Downloaded from https://academic.oup.com/jac/article-abstract/71/suppl_1/i21/2488613/Results-from-the-Survey-of-Antibiotic-Resistance
by Aga Khan University user
on 20 September 2017
Table 3. Distribution of MICs for S. pneumoniae isolates
Number of isolates at MIC (mg/L)
Country/antimicrobial n ≤0.002 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 128 .256
Democratic Republic of Congo
azithromycin 23 0 0 0 0 0 3 1 2 5 5 2 3 0 0 2 0 0 0 0
cefixime 23 0 0 0 1 0 3 3 1 7 3 2 1 1 0 0 1 0 0 0
cefuroxime 23 0 0 0 0 0 1 1 1 4 8 3 2 1 1 0 1 0 0 0
levofloxacin 23 0 3 1 0 6 1 0 0 4 3 3 2 0 0 0 0 0 0 0
ofloxacin 23 0 4 2 0 3 0 0 1 6 3 2 1 0 0 0 0 1 0 0
penicillin 23 0 0 0 0 0 0 4 4 2 2 3 1 4 1 0 2 0 0 0
SXT 23 0 1 2 0 1 0 1 1 6 5 1 0 0 1 0 1 3 0 0
≤0.002 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
Ivory Coast
AMC 110 0 0 0 35 0 37 17 11 8 1 0 1 0 0 0 0 0 0 0
cefaclor 110 0 0 0 0 0 0 0 0 1 18 47 25 14 3 0 1 1 0 0
cefuroxime 110 0 0 0 44 0 8 22 22 11 2 1 0 0 0 0 0 0 0 0
clarithromycin 110 0 0 0 35 0 51 17 1 0 1 0 0 1 0 0 1 0 0 3
levofloxacin 110 0 0 0 0 0 0 0 0 2 36 62 8 1 1 0 0 0 0 0
ofloxacin 110 0 0 0 0 1 0 1 0 0 4 14 75 10 3 1 1 0 0 0
penicillin 110 2 5 5 0 24 21 20 9 12 5 2 3 2 0 0 0 0 0 0
SXT 110 0 0 0 0 1 0 3 16 21 14 5 24 19 2 1 4 0 0 0
≤0.002 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 .256
Kenya
amoxicillina 64 0 0 0 9 0 4 3 3 9 4 14 13 1 1 3 0 0 0 0
AMC 84 0 0 0 17 0 3 3 15 7 4 21 10 1 1 1 0 0 0 1
azithromycina 64 0 0 0 0 0 0 0 0 1 2 18 17 4 4 1 2 0 0 15
ceftriaxone 84 0 0 4 0 10 0 7 11 11 26 12 1 1 1 0 0 0 0 0
cefuroxime 84 0 0 0 17 0 0 5 10 14 4 6 15 10 0 1 2 0 0 0
chloramphenicola 64 0 0 0 0 0 1 5 17 18 0 0 2 1 3 2 1 0 0 14
erythromycina 64 0 0 0 0 0 0 8 17 14 1 1 2 2 2 3 0 0 0 14
levofloxacina 20 0 0 0 0 0 0 0 0 1 11 8 0 0 0 0 0 0 0 0
moxifloxacin 84 0 0 0 0 0 1 9 60 13 1 0 0 0 0 0 0 0 0 0
penicillin 84 0 0 0 12 0 2 2 6 9 8 28 13 1 1 1 0 0 0 1
tetracyclinea 64 0 0 0 0 0 0 1 18 8 2 1 1 0 12 8 7 2 1 3
≤0.002 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
Senegal
AMC 14 0 0 0 8 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0
cefaclor 14 0 0 0 0 0 0 0 1 0 5 5 3 0 0 0 0 0 0 0
cefixime 14 0 0 0 0 0 0 0 3 3 5 1 2 0 0 0 0 0 0 0
cefuroxime 14 0 0 0 1 0 5 5 1 1 1 0 0 0 0 0 0 0 0 0
clarithromycin 14 0 0 0 1 0 3 4 6 0 0 0 0 0 0 0 0 0 0 0
clindamycin 14 0 0 0 0 0 0 4 5 5 0 0 0 0 0 0 0 0 0 0
levofloxacin 14 0 0 0 0 0 0 0 0 0 10 4 0 0 0 0 0 0 0 0
ofloxacin 14 0 0 0 0 0 0 0 0 0 0 3 11 0 0 0 0 0 0 0
penicillin 14 0 0 0 4 0 7 1 2 0 0 0 0 0 0 0 0 0 0 0
SXT 14 0 0 0 0 0 0 1 0 0 1 1 3 1 1 1 5 0 0 0
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole.
aNot all isolates were tested with this antibiotic.
SOAR: DRC, Ivory Coast, Senegal and Kenya 2011–14
i25
JAC
Downloaded from https://academic.oup.com/jac/article-abstract/71/suppl_1/i21/2488613/Results-from-the-Survey-of-Antibiotic-Resistance
by Aga Khan University user
on 20 September 2017
clarithromycin, levofloxacin and erythromycin. Susceptibility to all
other agents was ,80%, except to ofloxacin (85% susceptible).
Sample sizes for PRSP isolates were small for most agents, result-
ing in susceptibility estimates with wide confidence intervals.
Levofloxacin (95% susceptible) and amoxicillin/clavulanic acid
(86%) were the two most active agents against these isolates,
with all other agents showing susceptibility rates of ,70%.
Age group analysis
Differences in the susceptibility of S. pneumoniae from adult and
paediatric patients were investigated for isolates from the Ivory
Coast and Kenya (sample sizes ≥20). For Ivory Coast isolates, a
statistically significant difference was found only for ofloxacin,
with paediatric isolates almost 20 percentage points less suscep-
tible than isolates from adults (Figure 3). In Kenya no significant
differences between adult and paediatric patients were found
for any of the tested antimicrobials (data not shown).
H. influenzae
Isolates of H. influenzae were only collected from the Democratic
Republic of Congo and Senegal. The isolates from these countries
comprised 11 from paediatric patients (24%), 31 from adult
patients (67%) and 4 from elderly patients (9%).
Of the 23 H. influenzae isolates from Democratic Republic of
Congo, 22 (96%) came from middle ear effusion and one from
pleural fluid. The Senegal isolates came from sputum (14/23,
61%), tracheal aspirate (7/23, 30%) and middle ear effusion
(2/23, 9%).
In Democratic Republic of Congo, 9 of 23 isolates were
b-lactamase-positive (39.1%), whereas in Senegal it was only 1
of 23 (4.3%). Of the 14 b-lactamase-negative isolates in
Democratic Republic of Congo, 4 isolates (17.4% of all H. influen-
zae) were b-lactamase negative, ampicillin resistant by CLSI def-
inition (BLNAR, ampicillin MIC ≥4 mg/L), whereas in Senegal no
such isolates were found. Using the EUCAST BLNAR definition
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Table 4. MIC and susceptibility results for H. influenzae isolates
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial Isolate group n 50% 90% min max %S %I %R %S %S %I %R
Democratic Republic of Congo
AMCa,b all 23 1 16 0.03 32 73.9 (65.2)e 0 26.1 (34.8)e 69.6 (73.9) 69.6 (60.9)e 0 30.4 (39.1)e
BL2 14 0.5 8 0.03 16 78.6 0 21.4 78.6 (78.6) 78.6 0 21.4
ampicillin all 23 0.5 32 0.03 .256 69.6 8.7 21.7 NA 69.6 0 30.4
BL2 14 0.5 32 0.06 .256 71.4 0 28.6 NA 71.4 0 28.6
azithromycinc all 23 0.25 16 0.03 .256 82.6 0 17.4 NA NA NA NA
BL2 14 0.25 16 0.03 32 85.7 0 14.3 NA NA NA NA
cefaclorb all 23 0.25 4 0.03 8 100 (82.6)e 0 0 (17.4)e 73.9 NA NA NA
BL2 14 0.25 2 0.03 4 100 0 0 71.4 NA NA NA
cefixime all 23 0.5 16 ≤0.015 16 82.6 0 17.4 82.6 30.4 0 69.6
BL2 14 0.25 16 ≤0.015 16 85.7 0 14.3 85.7 35.7 0 64.3
cefuroximeb,d all 23 0.5 4 0.03 16 95.7 (78.3)e 0 4.4 (21.7)e 78.3 26.1 (21.7)e 52.2 (47.8)e 21.7 (30.4)e
BL2 14 0.5 4 0.03 16 92.9 0 7.1 71.4 21.4 50.0 28.6
ciprofloxacin all 23 0.25 2 0.004 4 82.6 0 17.4 82.6 82.6 0 17.4
BL2 14 0.25 2 0.004 4 85.7 0 14.3 85.7 85.7 0 14.3
clarithromycinc all 23 0.25 16 0.03 .256 95.7 0 4.4 NA NA NA NA
BL2 14 0.25 16 0.03 .256 92.9 0 7.1 NA NA NA NA
SXT all 23 0.5 .32 0.004 .32 60.9 17.4 21.7 60.9 60.9 8.7 30.4
BL2 14 0.5 .32 0.004 .32 57.1 14.3 28.6 57.1 57.1 7.1 35.7
Senegal
AMCa,b All 23 0.5 2 0.12 4 100 0 0 95.7 (100) 95.7 (91.3)e 0 4.3 (8.7)e
BL2 22 0.5 1 0.12 4 100 0 0 95.5 (100) 95.5 0 4.6
ampicillin all 23 0.25 1 0.06 2 91.3 8.7 0 NA 91.3 0 8.7
BL2 22 0.25 1 0.06 2 90.9 9.1 0 NA 90.9 0 9.1
cefaclorc all 23 4 16 1 64 87.0 8.7 4.3 0 NA NA NA
BL2 22 4 16 1 64 86.4 9.1 4.6 0 NA NA NA
cefixime all 23 0.06 0.12 ≤0.015 0.5 100 0 0 100 91.3 0 8.7
BL2 22 0.06 0.12 ≤0.015 0.5 100 0 0 100 90.9 0 9.1
cefuroximeb,d all 23 1 4 0.25 4 100 0 0 82.6 0 82.6 17.4
BL2 22 1 2 0.25 4 100 0 0 86.4 0 86.4 13.6
ciprofloxacin all 23 0.015 0.03 0.004 32 95.7 0 4.3 95.7 95.7 0 4.3
BL2 22 0.015 0.03 0.004 32 95.5 0 4.6 95.5 95.5 0 4.6
clarithromycinc all 23 8 16 2 32 95.7 4.3 0 NA NA NA NA
BL2 22 8 16 2 32 95.5 4.6 0 NA NA NA NA
levofloxacin all 23 0.015 0.015 0.008 32 95.7 0 4.3 95.7 95.7 0 4.3
BL2 22 0.015 0.015 0.008 32 95.5 0 4.6 95.5 95.5 0 4.6
ofloxacin all 23 0.03 0.06 0.015 32 95.7 0 4.3 NA 95.7 0. 4.3
BL2 22 0.03 0.06 0.015 32 95.5 0 4.6 NA 95.5 0 4.6
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(MIC ≥2 mg/L), the number of isolates from the Democratic
Republic of Congo remained at four (17.4%) and two isolates
(10.0%) were found in Senegal. For analysis, the BLNAR strains
from Democratic Republic of Congo were included with the
other b-lactamase-negative isolates.
Summary MIC and susceptibility data for H. influenzae are
shown in Table 4. MIC distribution data are given in Table 5. In
the Democratic Republic of Congo, amoxicillin/clavulanic acid
in vitro susceptibility was 73.9% for H. influenzae by CLSI and
high-dose PK/PD breakpoints, but slightly lower, at 69.6%, using
low-dose PK/PD and EUCAST criteria. However, all BLNAR strains
(four by CLSI or EUCAST) under clinical conditions should be con-
sidered non-susceptible to amoxicillin/clavulanic acid, cefaclor
and cefuroxime, irrespective of the MIC. With this correction, clin-
ical susceptibility to amoxicillin/clavulanic acid was reduced to
65.2% by CLSI and to 60.9% by EUCAST. In Senegal,.90% of iso-
lates were susceptible to amoxicillin/clavulanic acid irrespective of
the breakpoint used. Ciprofloxacin, levofloxacin, ofloxacin and cla-
rithromycin also showed high activity in this country, with suscep-
tibility rates of.90% by all breakpoints. In contrast, in Democratic
Republic of Congo, cefuroxime, cefaclor and clarithromycin
showed .95% susceptibility, whereas ampicillin and trimetho-
prim/sulfamethoxazole showed susceptibility of ,70% based on
CLSI breakpoints. In both countries, the proportion of isolates sus-
ceptible to cefuroxime and cefixime varied markedly depending
on the breakpoints used, due to the differences between CLSI,
EUCASTand PK/PD for these antibiotics. Cefuroxime in vitro activity
was .95% in both countries by the CLSI breakpoint but dropped
to 78.3% and 26.1% by PK/PD and EUCAST breakpoints, respect-
ively, in Democratic Republic of Congo and to 82.6% and 0%,
respectively, in Senegal. Cefixime was active against 82.6% of iso-
lates based on CLSI and PK/PD breakpoints in Democratic Republic
of Congo but susceptibility dropped to 30.4% based on EUCAST
breakpoints. In Senegal, 100% of isolates were susceptible to cefi-
xime and 87% to cefaclor based on CLSI breakpoints. Based on
EUCAST breakpoints, percentage susceptibility to cefixime was
91.3% and to cefaclor by PK/PD was 0%. Ampicillin activity was
69.6% by CLSI and EUCAST breakpoints in Democratic Republic of
Congo and 91.3% in Senegal. Trimethoprim/sulfamethoxazole
showed the lowest activity, with 60.9% susceptible across all break-
points in Democratic Republic of Congo and only 8.7% in Senegal.
Discussion
There is a paucity of antimicrobial surveillance data for Africa in
peer-reviewed journals, especially in the central region, with the lim-
ited available data showing marked variation between different
geographical regions within Africa as well as an increasing trend
in resistance over time.5,6 These findings underscore the importance
of monitoring susceptibility trends at the country or local level, and
incorporating the most recent susceptibility patterns into empirical
therapy decisions. This study provides country-specific antimicrobial
surveillance data for several countries across West, Central and East
Africa for the period 2011–14. Sample sizes were generally limited,
especially for isolates from Senegal, but it has recently been high-
lighted that increased surveillance is important in Africa even if
only small size samples are available.6
Previous data from SOAR for Africa in 2007 –09 showed
variable penicillin susceptibility in S. pneumoniae from NigeriaTa
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(26.6%), Kenya (33.3%), Senegal (66%) and the Ivory Coast
(89%).11,12 Very similar data for penicillin susceptibility were
observed in 2004– 06 for the Ivory Coast and Senegal (data
were not reported for Nigeria and Kenya).13 The current study
has seen penicillin susceptibility reduced in the Ivory Coast (to
70%) and reduced even further in Kenya (19%). The current level
of penicillin susceptibility in Senegal would appear to have
increased in 2011–14 compared with earlier time periods, but
this may simply be an artefact due to the small sample size in
the current study. In SOAR 2004–06 and 2007–09, macrolide sus-
ceptibility was high, at≥85%, in all African countries.11–13 This was
also true for the current time period, 2011–14, with the exception
of Kenya, where 64.1% erythromycin and 65.6% azithromycin sus-
ceptibility was observed. In the current study b-lactamase preva-
lence in H. influenzae from Senegal was low (4%) but the previous
SOAR report in 2007–09 indicated higher levels, at 27%.12 As men-
tioned above, this may relate to the small sample size.
Several antimicrobial agents were found to have strong activity
against respiratory pathogens across most of the African coun-
tries included in this study. Using CLSI breakpoints, both organ-
isms in this study showed .90% susceptibility to amoxicillin/
clavulanic acid, except for H. influenzae in Democratic Republic
of Congo (73.9% susceptible based on CLSI breakpoints).
Cefuroxime demonstrated strong activity against both species,
except S. pneumoniae in Democratic Republic of Congo and
Kenya. Both species generally demonstrated susceptibility
to macrolides (83% or higher), except for S. pneumoniae in
Kenya, where all tested macrolides showed susceptibility ,70%.
In contrast to these generally very active antimicrobials, several
agents that are widely used in Africa showed high resistance
rates. Susceptibility to trimethoprim/sulfamethoxazole did not
exceed 75% in any country against either species, with suscepti-
bility as low as 14.3% and 8.7% for S. pneumoniae and H. influen-
zae, respectively, in Senegal (albeit with small sample sizes).
Similarly, chloramphenicol showed low activity in Kenya (the
only country where the agent was tested) against S. pneumoniae
(68.7% susceptible). S. pneumoniae penicillin susceptibility was
only 17.4% in Democratic Republic of Congo, 19% in Kenya,
70% in Ivory Coast and 85.7% in Senegal based on CLSI penicillin
oral breakpoints. These results are especially important because
PISP and PRSP isolates were usually multiply resistant.
The data from this study confirm that isolates of S. pneumo-
niae susceptible to penicillin G are also susceptible to other
penicillins as inferred by CLSI and EUCAST guidelines and cepha-
losporins as inferred by CLSI guidelines. Interestingly, the data
from this study found the reverse was not always true using
CLSI breakpoints; i.e. all penicillin-non-susceptible S. pneumoniae
were susceptible to amoxicillin/clavulanic acid (amoxicillin) and
most were also susceptible to ceftriaxone. Therefore, either
the amoxicillin/clavulanic acid or ceftriaxone breakpoints are
not correct or the CLSI cross-resistance statement within the
b-lactam class is not correct. This warrants further investigation.
Table 5. Distribution of H. influenzae MICs
Number of isolates at MIC (mg/L)
Country/antimicrobial n 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 .256
Democratic Republic of Congo
AMC 23 0 0 0 0 1 1 2 1 4 4 3 1 2 2 2 0 0
ampicillin 23 0 0 0 0 1 1 0 4 6 4 2 1 0 1 2 0 1
azithromycin 23 0 0 0 0 3 4 4 2 2 2 0 2 0 2 1 0 1
cefaclor 23 0 0 0 0 4 2 2 6 3 2 1 1 2 0 0 0 0
cefixime 23 0 0 1 0 6 0 0 4 6 2 0 0 0 4 0 0 0
cefuroxime 23 0 0 0 0 3 2 1 5 3 4 2 2 0 1 0 0 0
ciprofloxacin 23 1 2 0 4 1 0 2 6 3 0 2 2 0 0 0 0 0
clarithromycin 23 0 0 0 0 4 3 1 5 4 1 0 2 0 2 0 0 1
SXT 23 2 1 0 0 0 3 0 1 7 2 2 1 1 0 0 3 0
n 0.004 0.008 ≤0.015 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 256
Senegal
AMC 23 0 0 0 0 0 0 1 3 10 6 2 1 0 0 0 0 0
ampicillin 23 0 0 0 0 0 1 3 8 6 3 2 0 0 0 0 0 0
cefaclor 23 0 0 0 0 0 0 0 0 0 1 9 8 2 2 0 1 0
cefixime 23 0 0 1 0 7 8 5 1 1 0 0 0 0 0 0 0 0
cefuroxime 23 0 0 0 0 0 0 0 1 4 14 1 3 0 0 0 0 0
ciprofloxacin 23 2 4 0 11 5 0 0 0 0 0 0 0 0 0 1 0 0
clarithromycin 23 0 0 0 0 0 0 0 0 0 0 4 7 9 2 1 0 0
levofloxacin 23 0 7 0 14 1 0 0 0 0 0 0 0 0 0 1 0 0
ofloxacin 23 0 0 0 4 10 8 0 0 0 0 0 0 0 0 1 0 0
SXT 23 0 0 0 0 0 0 2 0 0 1 0 0 0 1 19 0 0
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole.
SOAR: DRC, Ivory Coast, Senegal and Kenya 2011–14
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Comparing our results with findings in the literature is limited
not only because of paucity of data from Africa, but also because
different studies have reported data from different countries. For
example, two reports using data from the Tigecycline Evaluation
and Surveillance Trial (T.E.S.T) included mainly North African coun-
tries and South Africa.3,4 Comparing the current study with studies
that focused exclusively or predominantly on sub-Saharan Africa,
we saw several similar patterns. S. pneumoniae and H. influenzae
have been shown to have low susceptibility to trimethoprim/sulfa-
methoxazole, either in all African regions or in West Africa, with
resistance increasing for both organisms.5,6 Trimethoprim/sulfa-
methoxazole is commonly used in Africa for a broad range of bac-
terial infections as well as for routine prophylaxis in HIV patients,
yet current susceptibility levels in our study, as well as findings in
the literature, make its effectiveness against respiratory patho-
gens doubtful. Similarly, chloramphenicol, another inexpensive,
widely used antibiotic, was shown to have low activity against
H. influenzae.5,6 Our data agree with the recommendation to
use this agent in sub-Saharan Africa only if appropriate suscepti-
bility results are available.6 Our study showed low tetracycline
activity against S. pneumoniae in Kenya (the only country that
tested this agent), similar to findings in a meta-analysis of three
decades of published studies.5 In contrast, a recent systematic
review found tetracycline resistance to be high in West Africa,
but less so in East Africa.6 Interestingly, tetracycline resistance
may be due in part to environmental contamination with this
agent, as it is widely used in agriculture.5 Similar to a review of
macrolide susceptibility in sub-Saharan Africa,14 the current
study found generally good activity of macrolides against S. pneu-
moniae, with the notable exception of isolates from Kenya. For H.
influenzae, on the other hand, the current study found higher
macrolide activity compared with 70% susceptibility reported
in the macrolide review,14 although sample sizes were small in
both studies. Interestingly, in the macrolide review, isolates
from younger children tended to be more susceptible,14 while in
the current study macrolide susceptibility estimates were very
similar in children and adults.
Comparisons between studies are often difficult because dif-
ferent breakpoints are used or the MIC interpretive criteria are
not even reported.6 This is especially pertinent for S. pneumoniae.
Not only do the penicillin breakpoints for S. pneumoniae differ
between CLSI and EUCAST, but the CLSI guidelines themselves
include three separate breakpoints for oral, parenteral (non-
meningitis) and parenteral (meningitis) penicillin, with studies
frequently not specifying which were used. Different breakpoints
can result in dramatically diverging susceptibility estimates, a
problem clearly illustrated in the current study by widely varying
susceptibility results for cefaclor, ofloxacin and cefuroxime based
on CLSI, PK/PD and EUCAST breakpoints. For assessing comparability
between studies it is crucial that future studies clearly identify which
breakpoints were used. Furthermore, MIC interpretive criteria should
be better aligned, avoiding different breakpoints altogether and thus
avoiding confusion among healthcare providers making therapy
decisions and among microbiologists trying to compare results
from different geographical regions and time periods.
The main limitations of this study stem from small sample
sizes and the attempt to draw conclusions about antimicrobial
susceptibility levels in the country using data from mainly one
hospital site. However, despite these limitations, patterns
emerged that can be useful for clinicians in selecting empirical
therapy for CAP. Some of these patterns were not unexpected
considering other publications, such as the high resistance levels
to trimethoprim/sulfamethoxazole found across all four partici-
pating countries. Others were surprising, such as the high macro-
lide resistance of S. pneumoniae isolates from Kenya. These
results highlight the importance of ensuring access to antimicro-
bial agents beyond the inexpensive first-level drugs that are
widely used in Africa, as well as the need for continued monitoring
of antimicrobial resistance at the country and even the local level.
Acknowledgements
We would like to thank Nathalie Guessennd (Institute Pasteur, Ivory
Coast), Mireille Dosso (Institute Pasteur, Ivory Coast), Cheikh Boye
(Institute Pasteur, Senegal) and Jean Jacques Muyembe Tamfun (INRB,
Democratic Republic of Congo) for their participation in the study. We
would also like to thank Dr Keith Barker (GSK) for reviewing the manuscript.
Funding
This work was funded by GlaxoSmithKline.
Transparency declarations
This article forms part of a Supplement sponsored by GlaxoSmithKline.
D. Torumkuney, W. Mwiti and M. J. Anguibi-Pokou are employees of
GlaxoSmithKline. D. Torumkuney and W. Mwiti also hold shares in
GlaxoSmithKline. I. Morrissey is an employee of IHMA, a medical commu-
nication and consultancy company, who participated in the exploration,
interpretation of the results and preparation of this manuscript on behalf
of GSK. IHMA also provided medical writing support in the form of writing
assistance, collating author’s comments, grammatical editing and referen-
cing that was paid for by GSK. All other authors declare that they have no
conflict of interest.
Editorial assistance was provided by Tracey Morris, Livewire Editorial
Communications.
References
1 World Health Organization. Word Health 2014. Part III. Global health
indicators. http://www.who.int/gho/publications/world_health_statistics/
EN_WHS2014_Part3.pdf?ua=1.
2 Kariuki S, Dougan G. Antibacterial resistance in sub-Saharan Africa: an
underestimated emergency. Ann N Y Acad Sci 2014; 1323: 43–55.
3 Brandon M, Dowzicky MJ. Antimicrobial susceptibility among
Gram-positive organisms collected from pediatric patients globally
between 2004 and 2011: results from the Tigecycline Evaluation and
Surveillance Trial. J Clin Microbiol 2013; 51: 2371–8.
4 Tomic V, Dowzicky MJ. Regional and global antimicrobial susceptibility
among isolates of Streptococcus pneumoniae and Haemophilus influenzae
collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004–
2008). Ann Clin Microbiol Antimicrob 2014; 13: 52–9.
5 Ginsburg AS, Tinkham L, Riley K et al. Antibiotic non-susceptibility among
Streptococcus pneumoniae and Haemophilus influenzae isolates identified
in African cohorts: a meta-analysis of three decades of published studies.
Int J Antimicrob Agents 2013; 42: 482–91.
6 Leopold SJ, van Leth F, Tarekegn H et al. Antimicrobial drug
resistance among clinically relevant bacterial isolates in sub-Saharan
Africa: a systematic review. J Antimicrob Chemother 2014; 69:
2337–53.
Kacou-Ndouba et al.
i30
Downloaded from https://academic.oup.com/jac/article-abstract/71/suppl_1/i21/2488613/Results-from-the-Survey-of-Antibiotic-Resistance
by Aga Khan University user
on 20 September 2017
7 Clinical and Laboratory Standards Institute. Performance Standards for
Antimicrobial Disk Susceptibility Tests—Eleventh Edition: Approved Standard
M02-A11. CLSI, Wayne, PA, USA, 2012.
8 Clinical and Laboratory Standards Institute. Performance Standards
for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational
Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
9 The European Committee on Antimicrobial Susceptibility testing.
Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version
4.0, 2014. http://www.eucast.org.
10 Anon JB, Jacobs MR, Poole MD et al. Antimicrobial treatment guidelines
for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130
Suppl 1: 1–45.
11 Iregbu KC, Sonibare SA, Nwoked E et al. Antibacterial resistance among
Streptococcus pneumoniae from three centres in Nigeria: results from the
Survey of Antibiotic Resistance (SOAR) 2007–2009. In: Abstracts of the
26th Paediatric Association Congress of Paediatrics, Johannesburg, South
Africa, 2010. Abstract 1434.
12 Torumkuney O’Brien D, SOAR Study group. Antibacterial resistance
among Streptococcus pneumoniae, Haemophilus influenzae and
Streptococcus pyogenes from 9 countries in Africa and the Middle East:
results from the Survey of Antibiotic Resistance (SOAR) 2007–2009. In:
Abstracts of the 49th Interscience Conference on Antimicrobial Agents
and Chemotherapy, San Francisco, USA, 2009. Abstract C2–1402, p. 118.
American Society for Microbiology, Washington, DC, USA. (Poster/Data on
file GSK-2014N216846_00, 2014).
13 Sievers J, SOAR Study Group. Antibacterial resistance among
Streptococcus pneumoniae from 8 countries in Africa and the Middle
East: results from the Survey of Antibiotic Resistance (SOAR) 2004–2006.
In: Abstracts of the 46th Interscience Conference on Antimicrobial Agents
and Chemotherapy, San Francisco, USA, 2006. Abstract C2-0425.
American Society for Microbiology, Washington, DC, USA.
14 Lubell Y, Turner P, Ashley EA et al. Susceptibility of bacterial
isolates from community-acquired infections in sub-Saharan Africa and
Asia to macrolide antibiotics. Trop Med Int Health 2011; 16: 1192–205.
SOAR: DRC, Ivory Coast, Senegal and Kenya 2011–14
i31
JAC
Downloaded from https://academic.oup.com/jac/article-abstract/71/suppl_1/i21/2488613/Results-from-the-Survey-of-Antibiotic-Resistance
by Aga Khan University user
on 20 September 2017
